In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics

被引:48
作者
Alhambra, A
Cuadros, JA
Cacho, J
Gómez-Garcés, JL
Alós, JI
机构
[1] Hosp Mostoles, Dept Microbiol, Madrid 28935, Spain
[2] Hosp Univ Principe Asturias, Dept Microbiol, Madrid, Spain
[3] Hosp Univ Getafe, Dept Microbiol, Madrid, Spain
关键词
carbapenems; antibiotic susceptibility; urinary tract infections;
D O I
10.1093/jac/dkh218
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Background: The treatment of complicated urinary tract infections may require the use of a parenteral antibiotic with potent activity against the most common urinary pathogens. Ertapenem is a broad-spectrum 1beta-methyl carbapenem with a long plasma half-life that allows administration of a single daily dose. Methods: The purpose of this work was to test the in vitro susceptibility to ertapenem, ampicillin, cefazolin, cefuroxime, cefotaxime, co-amoxiclav, piperacillin/tazobactam, imipenem, gentamicin, amikacin, fosfomycin, ciprofloxacin and co-trimoxazole of 482 strains of urinary pathogens of the family Enterobacteriaceae isolated from patients in the community of Madrid (40% from males). The distribution was as follows: Escherichia coli (n = 315), Proteus mirabilis (n = 42), Klebsiella spp. (n = 14) and AmpC-producing Enterobacteriaceae (n = 111). The strains studied were selected based on their resistance to quinolones and aminoglycosides, and their production of extended-spectrum beta-lactamases (ESBLs) or AmpC-type beta-lactamases. Results: All the strains were susceptible to ertapenem, imipenem and amikacin. The MIC90 of ertapenem ranged from a minimum of 0.03 mg/L for Proteus vulgaris and a maximum of 1 mg/L for Enterobacter spp. Ertapenem was the most active of all drugs tested in all cases. On comparing antibiotic resistance among ESBL-producing strains of E. coli (n = 35) and E. coli strains not producing ESBLs (n = 280), statistically significant differences were obtained for ciprofloxacin (P = 0.002) and gentamicin (P = 0.011). Regarding ertapenem, only a slight increase in MIC50 was seen, the value being 0.015 mg/L for strains not producing ESBLs versus 0.03 mg/L for ESBL-producing strains. Conclusions: In view of its significant antibiotic potency against antibiotic-resistant Enterobacteriaceae, ertapenem may constitute a good therapeutic alternative in urinary infections caused by these pathogens.
引用
收藏
页码:1090 / 1094
页数:5
相关论文
共 12 条
[1]
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[2]
A review of its microbiologic, pharmacokinetic and clinical aspects [J].
Cunha, BA .
DRUGS OF TODAY, 2002, 38 (03) :195-213
[3]
Carbapenems:: the pinnacle of the β-lactam antibiotics or room for improvement? [J].
Edwards, JR ;
Betts, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (01) :1-4
[4]
In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) :703-706
[5]
In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1915-1918
[6]
In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345) [J].
Gill, CJ ;
Jackson, JJ ;
Gerckens, LS ;
Pelak, BA ;
Thompson, RK ;
Sundelof, JG ;
Kropp, H ;
Rosen, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :1996-2001
[7]
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults [J].
Jimenez-Cruz, F ;
Jasovich, A ;
Cajigas, J ;
Jiang, Q ;
Imbeault, D ;
Woods, GL ;
Gesser, RM .
UROLOGY, 2002, 60 (01) :16-22
[8]
In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum p-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates [J].
Kohler, J ;
Dorso, KL ;
Young, K ;
Hammond, GG ;
Rosen, H ;
Kropp, H ;
Silver, LL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1170-1176
[9]
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia [J].
Livermore, DM ;
Carter, MW ;
Bagel, S ;
Wiedemann, B ;
Baquero, F ;
Loza, E ;
Endtz, HP ;
van den Braak, N ;
Fernandes, CJ ;
Fernandes, L ;
Frimodt-Moller, N ;
Rasmussen, LS ;
Giamarellou, H ;
Giamarellos-Bourboulis, E ;
Jarlier, V ;
Nguyen, J ;
Nord, CE ;
Struelens, MJ ;
Nonhoff, C ;
Turnidge, J ;
Bell, J ;
Zbinden, R ;
Pfister, S ;
Mixson, L ;
Shungu, DL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1860-1867
[10]
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection [J].
Pelak, BA ;
Citron, DM ;
Motyl, M ;
Goldstein, EJC ;
Woods, GL ;
Teppler, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (05) :735-741